Comparative activity of melarsoprol and arsenic trioxide in chronic B- cell leukemia lines

Blood

Volumn 90, Issue 2, 1997, Pages 562-570

  König, Andrea ^a   Wrazel, Laura ^b   Warrell Jr , Raymond P ^b   Rivi, Roberta ^b   Pandolfi, Pier Paolo ^b   Jakubowski, Ann ^b   Gabrilove, Janice L ^b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC TRIOXIDE; MELARSOPROL;

APOPTOSIS; ARTICLE; B CELL LEUKEMIA; CELL DEATH; CELL VIABILITY; CHRONIC LYMPHATIC LEUKEMIA; CONCENTRATION RESPONSE; DOSE RESPONSE; DOSE TIME EFFECT RELATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; LYMPHOPROLIFERATIVE DISEASE; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTEIN EXPRESSION;

EID: 0038125071     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v90.2.562     Document Type: Article

References (30)

1. Bainbridge WS: the Cancer Problem. New York, NY, Macmillan, 1914, p 271
2. Forkner C, McNair-Scott TF: Arsenic as a therapeutic agent in chronic myeloid leukemia. JAMA 97:305, 1931
3. Kandel EV, Leroy GV: Chronic arsenical poisening during the treatment of chronic myeloid leukemia. Arch Intern Med 60:846, 1937
4. Sun HD, Ma L, Hu XL, Zhang TD: Ai-Lin I treated 32 cases of acute promyelocytic leukemia. Chin J Intergrat Chin Western Med 12:170, 1992
5. 3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. Blood 88:1052, 1996
6. Ercoli N, Wilson W: Influence of BAL on the toxicity and chemotherapeutic activity of marpharsen. J Pharmacol Exp Therapeutics 92:121, 1948
7. Friedheim EAH: The active form of tryparsamide TPB in the treatment of human trypanosomiasis. Am J Trop Med 29:173, 1949
8. Dighiero G, Travade P, Chevret S, Fenaux P, Chastang C, Binet JL: B-cell chronic lymphocytic leukemia: Present status and future directions. French Cooperative Group on CLL (Review). Blood 78:1901, 1991
9. Cheson B, Bennet J, Rai K, Grever M, Kay N, Schiffer C, Oken M, Keating M, Boldt B, Kempin S, Foon K: Guidelines for the classsification of chronic lymphocytic leukemia: Recommendations of the National Cancer Institute-sponsored working group. Am J Hematol 29:152, 1988
10. Melo JV, Brito-Babapulle V, Foroni L, Robinson DS, Luzzatto L, Catovsky D: Two new cell lines from B-prolymphocytic leukaemia: Characterization by morphology, immunological markers, karyotype and Ig gene rearrangement. Intern J Cancer 38:531, 1986
11. Melo JV, Foroni L, Brito-Babapulle V, Luzzatto L, Catovsky D: The establishment of cell lines from chronic B cell leukaemias: Evidence of leukaemic origin by karyotypic abnormalities and Ig gene rearrangement. Clin Exp Immunol 73:23, 1988
12. Wendel-Hansen V, Sallstrom J, De Campos-Lima PO, Kjellstrom G, Sandlund A, Siegbahn A, Carlsson M, Nilsson K, Rosen A: Epstein-Barr virus (EBV) can immortalize B-CLL cells activated by cytokines. Leukemia 8:476, 1994
13. Mohammad RM, Mohamed AN, Hamdan MY, Vo T, Chen B, Katato K, Abubakr YA, Dugan MC, al-Katib A: Establishment of a human B-CLL xenograft model: Utility as a preclinical therapeutic model. Leukemia 10:130, 1996
14. König A, Menzel T, Lynen S, Wrazel L, al-Katib A, Rosen A, Raveche E, Gabrilove JL: Basic fibroblast growth factor (bFGF) upregulates the expression of bcl-2 in chronic lymphocytic leukemia cell lines resulting in delaying apoptosis. Leukemia 11:258, 1997
15. Gorczyca W, Gong J, Ardelt B, Traganos F, Darzynkiewicz Z: The cell cycle related differences in susceptibility of HL-60 cells to apoptosis induced by various antitumor agents. Cancer Res 53:3186, 1993
16. 3 exerts dose-dependent dual effects on APL cells. Blood 89:3345, 1997
17. 3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 89:3354, 1997
18. Rivi R, Calleja E, König A, Lai L, Gambacorti-Passerini C, Scheinberg D, Gabrilove JL, Warrell RP Jr, Pandolfi PP: Organic arsenical melarsoprol shows growth suppressive activity via programmed cell death on APL and other myeloid and lymphoid leukemia derived cell lines. Blood 88:68a, 1996 (abstr. suppl 1)
19. Muller S, Walter RD, Fairlamb AH: Differential susceptibility of filarial and human erythrocyte glutathione reductase to inhibition by the trivalent organic arsenical melarsen oxide. Mol Biochem Parasitol 71:211, 1995
20. Le Cabec V, Maridonneau-Parini I: Complete and reversible inhibition of NADPH oxidase in human neutrophils by phenylarsine oxide at a step distal to membrane translocation of the enzyme subunits. J Biol Chem 270:2067, 1995
21. Rosen BP, Bhattacharjee H, Shi W: Mechanisms of metallo-regulation of an anion-translocating ATPase (review). J Bioenergetics Biomembranes 27:85, 1995
22. Robertson LE, Chubb S, Meyn RE, Story M, Ford R, Hittelman WN, Plunkett W: Induction of apoptotic cell death in chronic lymphocytic leukemia by 2-chloro-2′-deoxyadenosine and 9-beta-D-arabinosyl-2-fluoroadenine. Blood 81:143, 1993
23. Dancescu M, Rubio-Trujillo M, Biron G, Bron D, Delespesse G, Sarfati M: Interleukin 4 protects chronic lymphocytic leukemic B cells from death by apoptosis and upregulates Bcl-2 expression. J Exp Med 176:1319, 1992
24. McConkey DJ, Hartzell P, Jondal M, Orrenius S: Inhibition of DNA fragmentation in thymocytes and isolated thymocyte nuclei by agents that stimulate protein kinase C. J Biol Chem 264:13399, 1989
25. Hoffbrand AV, Panayiotidis P, Reittie J, Ganeshaguru K: Autocrine and paracrine growth loops in chronic lymphocytic leukemia (review). Semin Hematol 30:306, 1993
26. Liu Y, Grander D, Soderhall S, Juliusson G, Gahrton G, Einhorn S: Retinoblastoma gene deletions in B-cell chronic lymphocytic leukemia. Genes Chromosom Cancer 4:250, 1992
27. Fenaux P, Preudhomme C, Lai JL, Quiquandon I, Jonveaux P, Vanrumbeke M, Sartiaux C, Morel P, Loucheux-Lefebvre MH, Bauters F, Berger R, Kerchaert JP: Mutations of the p53 gene in B-cell chronic lymphocytic leukemia: A report on 39 cases with cytogenetic analysis. Leukemia 6:246, 1992
28. Delmer A, Ajchenbaum-Cymbalista F, Tang R, Ramond S, Faussat AM, Marie JP, Zittoun R: Overexpression of cyclin D2 in chronic B-cell malignancies. Blood 85:2870, 1995
29. Hanada M, Delia D, Aiello A, Stadtmauer E, Reed JC: bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia. Blood 82:1820, 1993
30. Soignet S, Rivi R, long WP, Gabrilove J, Scheinberg DA, Pandolfi PP, Warrell RP Jr: Clinical and laboratory studies in leukemia of an organic arsenical, melarsoprol. Proc Am Soc Clin Oncol 16:4a, 1997 (abstr)